FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 334:333-334 February 1, 1996 Number 5 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Charache, S. PubMed Citation

To the Editor: We wish to comment further on the possible risks of hydroxyurea therapy in sickle cell disease, a subject of considerable attention since the results of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia were reported by Charache et al. (May 18 issue).¹

We agree that the caution advised by Ho and Murgo² and Silver³ in their letters (Oct. 12 issue) is necessary. Unfortunately, the single sentence from our editorial⁴ quoted by Ho and Murgo distorts the thrust of our paragraph on the long-term safety of hydroxyurea. Continued monitoring of patients with sickle cell disease and others . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Atweh, G. F., Sutton, M., Nassif, I., Boosalis, V., Dover, G. J., Wallenstein, S., Wright, E., McMahon, L., Stamatoyannopoulos, G., Faller, D. V., Perrine, S. P. (1999). Sustained Induction of Fetal Hemoglobin by Pulse Butyrate Therapy in Sickle Cell Disease. Blood 93: 1790-1797 [Abstract] [Full Text]